文献速递妇科肿瘤

DNA甲基化检测诊断高级别宫颈上皮内瘤变及宫颈癌的准确性:系统综述与荟萃分析

Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2026-05-27

该系统综述与荟萃分析评估了DNA甲基化标志物检测CIN2+、CIN3+及宫颈癌的诊断准确性,纳入51项研究(28,977例HPV+女性)和125项研究(49,242例女性)。在HPV+女性中,JAM3、C13ORF18和PAX1的DOR最高,EPB41L3的LR-最低;在所有女性中,SOX1的DOR最高。多种甲基化标志物对CIN3+检测显示良好敏感性并保持高特异性,有望减少不必要的阴道镜转诊。

要点

  • 在HPV+女性中,JAM3、C13ORF18和PAX1对CIN2+及以上病变的诊断优势比最高。
  • EPB41L3在HPV+女性中具有最低的阴性似然比(0.26),有助于排除病变。
  • 甲基化标志物可能适用于不宜细胞学检查的自取样进行有效分诊,但需进一步在筛查队列中研究。

核心结论

  • 多种甲基化标志物对CIN3+检测报告了良好敏感性并保持高特异性,有望减少不必要的阴道镜转诊。
  • 甲基化标志物可能允许对不适合细胞学的自取样进行有效分诊,但理想情况下需在筛查队列中进一步研究。

研究设计与样本

  • 系统综述与荟萃分析(注册号CRD42022299760),系统检索三个数据库至2025年3月。
  • 纳入51项研究探索13种甲基化标志物(28,977例HPV+女性),以及总共125项研究评估32种标志物(49,242例女性)。
  • 采用双变量随机效应模型汇总每种标志物在各终点的敏感性、特异性、诊断优势比(DOR)、阳性与阴性似然比(LR+、LR-)。
  • 主要分析在HPV+女性中进行,次要分析包括所有数据 regardless of HPV positivity。

主要发现

  • 在HPV+女性中,DOR最高的标志物为JAM3(20.82 [95%CI 14.41-30.08])、C13ORF18(19.50 [95%CI 11.65-32.65])和PAX1(17.13 [95%CI 9.20-31.89])。
  • EPB41L3在HPV+女性中具有最低的LR-(0.26 [95%CI 0.19-0.35])。
  • 在所有女性中,SOX1的DOR最高(29.72 [95%CI 12.84-68.81]),JAM3和PAX1保持良好准确性(DOR分别为26.73 [95%CI 19.97-35.77]和23.96 [95%CI 17.32-33.15])。

临床怎么用

  • DNA甲基化检测可作为HPV+女性的潜在分诊工具,以减少不必要的阴道镜转诊。
  • 对于不适合细胞学检查的自取样,甲基化标志物可能提供有效的分诊选择,但需进一步验证。

局限性

  • 原文未明确报告纳入研究的偏倚风险或异质性细节。
  • 甲基化标志物在自取样中的分诊效率需进一步在筛查队列中研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papillomavirus (HPV)-based cervical screening offers stronger protection against cervical intraepithelial neoplasia (CIN) than screening with cytology. DNA methylation tests have been proposed as an alternative triage test to cytology, although there is currently no consensus on the most accurate gene or gene panels ("markers"). METHODS: We conducted a meta-analysis of accuracy of human and HPV methylation markers to detect CIN2 or worse (CIN2+), CIN3+, and cervical cancer (CRD42022299760). We systematically searched three databases to March 2025. We used a bivariate random-effects model to produce pooled sensitivity, specificity, diagnostic odds ratios (DORs), positive and negative likelihood ratios (LR+, LR-) for each marker at each available endpoint. Our primary analysis was in HPV+ women, and secondary analysis included all data regardless of HPV positivity. RESULTS: We included 51 studies exploring 13 methylation markers in 28,977 HPV+ women, and in total 125 studies assessing 32 markers in 49,242 women. For HPV+, the markers with the highest DORs were JAM3 (20.82 [95%CI 14.41-30.08]), C13ORF18 (19.50 [95%CI 11.65-32.65]), and PAX1 (17.13 [95%CI 9.20-31.89]). EPB41L3 had the lowest LR- (0.26 [95%CI 0.19-0.35]). In all women, SOX1 had the highest DOR (29.72 [95%CI 12.84-68.81]), although JAM3 and PAX1 maintained good accuracy (DORs 26.73 [95%CI 19.97-35.77] and 23.96 [95%CI 17.32-33.15]). CONCLUSION: Several methylation markers reported good sensitivity in the detection of CIN3+ whilst maintaining high specificity. These have potential to reduce unnecessary referrals to colposcopy. Methylation markers may permit efficient triage on self-samples which are inappropriate for cytology, although this requires further study ideally in screening cohorts.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ellis LB, Tighe J, Bowden SJ, et al. Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis. Eur J Cancer. 2026. PMID: 42235467. doi:10.1016/j.ejca.2026.116823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。